Vaxcyte, Inc. — Director's Dealing 2023

Dec 11, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-12-07

Reporting Person: Eydelman Mikhail (SVP, Gen Counsel & Corp Sec)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-07	Common Stock	M	10000	$21.41	Acquired	31035	Direct
2023-12-07	Common Stock	S	10000	$56.50	Disposed	21035	Direct
2023-12-07	Common Stock	F	325	$56.78	Disposed	20710	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-07	Stock Option (right to buy)	$21.41	M	10000	Acquired	2032-05-08	Common Stock (10000)	Direct

Footnotes

F1: Includes 548 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.

F3: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F4: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.